Table 4. Characteristics of Patients With DPP-4 Inhibitor–Associated BP and Those With Non–DPP-4 Inhibitor–Associated BP^a.

Characteristic	DPP-4 Inhibitor–Associated BP (n = 36)	Non–DPP-4 Inhibitor–Associated BP (n = 46)	P Value
Age at diagnosis, y			.28
Mean (SD)	77.9 (9.8)	80.1 (8.3)
Median (range)	77.5 (59.0-94.0)	82.0 (56.0-95.0)
Sex			.056
Male	21 (58.3)	17 (37.0)
Female	15 (41.7)	29 (63.0)
Delay at diagnosis, mean (SD), mo	3.4 (3.2)	2.6 (2.7)	.22
Atypical clinical variants of BPb	5 (13.9)	4 (8.7)	.46
Distribution of bullous lesions
Mucosal involvement	8 (22.2)	3 (6.5)	.04
Limbs	35 (97.1)	46 (100)	.25
Trunk	35 (97.1)	41 (88.9)	.16
Hands and/or feet	12 (33.3)	17 (36.9)	.74
Head and neck	16 (44.4)	17 (37.8)	.55
Severity			.28
Extensive disease	20 (55.6)	20 (43.5)
Mild to moderate	16 (44.4)	26 (56.5)
Anti–basement membrane antibodies detected by indirect IF	14 (38.9)	26 (56.5)	.12
Treatment
Oral prednisone >1 mg/kg	22 (61.3)	30 (65.0)	.73
Prednisone dose at discharge, mean (SD), mg	39.4 (18.8)	42.6 (17.3)	.43
Adjuvant immunosuppressant	15 (41.7)	11 (23.9)	.09
Topical steroids	4 (11.1)	4 (8.7)	.72
Peripheral eosinophilia
Eosinophil count, mean (SD), cells/μL	399.8 (508.0)	1117.6 (1847.6)	.01
Other hematologic biomarkers, mean (SD)
WBC count, cells/μL	9163.0 (3082.6)	10 052.2 (3593.3)	.24
Platelet count, ×103/μL	226.5 (67.5)	264.4 (75.8)	.02
ESR, mm/h	35.4 (28.1)	34.1 (19.4)	.81

Abbreviations: BP, bullous pemphigoid; DPP-4 inhibitor, dipeptidyl peptidase 4 inhibitor; ESR, erythrocyte sedimentation rate; IF, immunofluorescence; WBC, white blood cell.

^aUnless otherwise indicated, data are reported as number (percentage) of participants.

^bIncluding the prurigo-like type, urticaria-like type, eczema-like type, and dyshidrosiform type.